On July 27, 2026, argenx, a global immunology innovation company, and Forte Biosciences, a clinical-stage biopharmaceutical company, announced that they have entered into a definitive agreement under which argenx will acquire Forte Biosciences for $77.00 per share in cash, representing a total equity value of approximately $2.2 billion. FB102, Forte Biosciences’ lead program, expands argenx’s portfolio of differentiated immunology medicines, adding a first-in-class anti-CD122 antibody with clinical proof-of-concept in vitiligo and celiac disease and potential to address multiple autoimmune diseases. Wilson Sonsini Goodrich & Rosati advised Forte Biosciences on the transaction.

Under the terms of the agreement, argenx, through a wholly owned subsidiary, will commence a cash tender offer to acquire all of the outstanding. Following the successful completion of the tender offer, a wholly owned subsidiary of argenx will merge with Forte Biosciences. The acquisition is expected to close in Q3 2026, subject to customary closing conditions.

The Wilson Sonsini team that advised Forte Biosciences on the transaction includes:

M&A
Rob Ishii
Remi Korenblit
Ryan Cooper
Melis Kilic

Corporate
Dan Koeppen
Ben Capps
Rob Wernli
Meg Moloney
Patrick Mullery

Employee Benefits and Compensation
Megan Schilling
Brandon Gantus
Jason Chan
Han Bae

Patents and Innovations
Michael Hostetler
Minyoung Shin

Technology Transactions
Mark Bellomy
Christina Fuleihan
Gopika Mesrobian

National Security
Joshua Gruenspecht
Anne Seymour
Nate Yang

Regulatory
Eva Yin

Employment and Trade Secrets
Matt Gorman

Data, Privacy, and Cybersecurity
Matthew Staples
Michael O'Brien
Alice Han

Tax
Myra Sutanto Shen
Rob Sherrill

Antitrust and Competition
Jamillia Ferris
Michelle Yost Hale
Miata Eggerly
Kimberley Biagioli
Deirdre Carroll

For more information, please see argenx’s news release.